GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » EV-to-FCF

Beijing Luzhu Biotechnology Co (HKSE:02480) EV-to-FCF : -14.95 (As of May. 13, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Beijing Luzhu Biotechnology Co's Enterprise Value is HK$6,389.09 Mil. Beijing Luzhu Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-427.44 Mil. Therefore, Beijing Luzhu Biotechnology Co's EV-to-FCF for today is -14.95.

The historical rank and industry rank for Beijing Luzhu Biotechnology Co's EV-to-FCF or its related term are showing as below:

HKSE:02480' s EV-to-FCF Range Over the Past 10 Years
Min: -20.69   Med: 0   Max: 0
Current: -14.95

HKSE:02480's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs HKSE:02480: -14.95

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-13), Beijing Luzhu Biotechnology Co's stock price is HK$26.55. Beijing Luzhu Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-1.367. Therefore, Beijing Luzhu Biotechnology Co's PE Ratio for today is At Loss.


Beijing Luzhu Biotechnology Co EV-to-FCF Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co EV-to-FCF Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23
EV-to-FCF
- - -

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF - - - - -

Competitive Comparison of Beijing Luzhu Biotechnology Co's EV-to-FCF

For the Biotechnology subindustry, Beijing Luzhu Biotechnology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Luzhu Biotechnology Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Luzhu Biotechnology Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Beijing Luzhu Biotechnology Co's EV-to-FCF falls into.



Beijing Luzhu Biotechnology Co EV-to-FCF Calculation

Beijing Luzhu Biotechnology Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6389.093/-427.443
=-14.95

Beijing Luzhu Biotechnology Co's current Enterprise Value is HK$6,389.09 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beijing Luzhu Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-427.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Luzhu Biotechnology Co  (HKSE:02480) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Beijing Luzhu Biotechnology Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=26.55/-1.367
=At Loss

Beijing Luzhu Biotechnology Co's share price for today is HK$26.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beijing Luzhu Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-1.367.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Beijing Luzhu Biotechnology Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Luzhu Biotechnology Co (HKSE:02480) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is our Core Product.

Beijing Luzhu Biotechnology Co (HKSE:02480) Headlines

No Headlines